论文部分内容阅读
目的 评价哌拉西林 /三唑巴坦 (PIP/TAZ)在治疗中、重症感染中的有效性及安全性。方法 选择 10 0例临床表现为中、重症感染的患者 ,给予 PIP/TAZ治疗。结果 临床痊愈率为 78%,有效率为 84%,细菌清除率为80 %,不良反应率为 3%。结论 PIP/TAZ在治疗中、重症感染是一种高效、安全的广谱抗菌药物。
Objective To evaluate the efficacy and safety of piperacillin / tazobactam (PIP / TAZ) in the treatment of severe and severe infections. Methods One hundred and ten patients with moderate or severe infection were selected and treated with PIP / TAZ. Results The clinical cure rate was 78%, the effective rate was 84%, the bacterial clearance rate was 80% and the adverse reaction rate was 3%. Conclusions In the treatment of PIP / TAZ, severe infection is an efficient and safe antimicrobial agent.